- Home
- LCTX vs STHO Comparison
LCTX vs STHO Comparison
Compare LCTX & STHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- STHO
- Stock Information
- Founded
- LCTX 1990
- STHO N/A
- Country
- LCTX United States
- STHO United States
- Employees
- LCTX N/A
- STHO N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- STHO Real Estate
- Sector
- LCTX Health Care
- STHO Real Estate
- Exchange
- LCTX Nasdaq
- STHO Nasdaq
- Market Cap
- LCTX 107.3M
- STHO 89.7M
- IPO Year
- LCTX N/A
- STHO N/A
- Fundamental
- Price
- LCTX $1.00
- STHO $7.16
- Analyst Decision
- LCTX Strong Buy
- STHO
- Analyst Count
- LCTX 5
- STHO 0
- Target Price
- LCTX $4.20
- STHO N/A
- AVG Volume (30 Days)
- LCTX 1.6M
- STHO 44.3K
- Earning Date
- LCTX 08-12-2025
- STHO 08-19-2025
- Dividend Yield
- LCTX N/A
- STHO N/A
- EPS Growth
- LCTX N/A
- STHO N/A
- EPS
- LCTX N/A
- STHO N/A
- Revenue
- LCTX $9,557,000.00
- STHO $102,485,000.00
- Revenue This Year
- LCTX N/A
- STHO N/A
- Revenue Next Year
- LCTX $244.95
- STHO N/A
- P/E Ratio
- LCTX N/A
- STHO N/A
- Revenue Growth
- LCTX 19.42
- STHO N/A
- 52 Week Low
- LCTX $0.37
- STHO $6.06
- 52 Week High
- LCTX $1.21
- STHO $14.50
- Technical
- Relative Strength Index (RSI)
- LCTX 50.84
- STHO 39.93
- Support Level
- LCTX $1.00
- STHO $7.07
- Resistance Level
- LCTX $1.09
- STHO $7.45
- Average True Range (ATR)
- LCTX 0.08
- STHO 0.21
- MACD
- LCTX -0.02
- STHO -0.09
- Stochastic Oscillator
- LCTX 24.25
- STHO 19.61
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.